{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:01:42Z","timestamp":1786636902888,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J App Basic Med Res"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/2229-516x.106347","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T03:19:47Z","timestamp":1358824787000},"page":"77","source":"Crossref","is-referenced-by-count":35,"title":["Vaptans: A new option in the management of hyponatremia"],"prefix":"10.4103","volume":"2","author":[{"given":"Suruchi","family":"Aditya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-516X.106347-1","first-page":"iii1","volume-title":"SIADH and Hyponatremia: Foreword","author":"O\u2032","year":"2009","journal-title":"NDT Plus"},{"key":"key-10.4103\/2229-516X.106347-2","first-page":"iii5","volume-title":"SIADH and hyponatremia: Why does it matter?","author":"Hoorn","year":"2009","journal-title":"NDT Plus"},{"key":"key-10.4103\/2229-516X.106347-3","first-page":"e1","volume-title":"Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits","author":"Renneboog","year":"2006","journal-title":"Am J Med"},{"key":"key-10.4103\/2229-516X.106347-4","first-page":"275","volume-title":"Hyponatremia independent of osteoporosis is associated with fracture occurrence","author":"Kinsella","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key-10.4103\/2229-516X.106347-5","unstructured":"Fukagawa M, Kurokawa K, Papadakis MA. Fluid and electrolyte disorders. In: Mc Phee SJ, Papadakis MA, Tierney LM Jr, editors. Current Medical Diagnosis and Treatment. 47 th ed. New York: Mc Graw Hill; 2008. p. 757-62."},{"key":"key-10.4103\/2229-516X.106347-6","doi-asserted-by":"crossref","unstructured":"In: Kumar P, Clark M, editors. Water, electrolytes and acid base balance. Kumar and Clark\u2032s Clinical Medicine. 7 th ed. Edinburgh: Saunders Elsevier; 2009. p. 649-63.","DOI":"10.1016\/B978-0-7020-2993-6.00017-1"},{"key":"key-10.4103\/2229-516X.106347-7","unstructured":"Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison\u2032s Principles of Internal Medicine. 16 th ed. Vol 1. New York: Mc Graw Hill; 2005. p. 252-62."},{"key":"key-10.4103\/2229-516X.106347-8","unstructured":"Robertson GL. Disorders of the neurohypophysis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison\u2032s Principles of Internal Medicine. 17 th ed. Vol 2. New York: Mc Graw Hill; 2008. p. 2222-4."},{"key":"key-10.4103\/2229-516X.106347-9","unstructured":"Boon NA, Colledge NR, Walker BR, Hunter JA, editors. Integrated water and electrolyte balance. Davidson\u2032s Principles and practice of Medicine. 10 th ed. Edinburgh: Churchill Livingstone; 2006. p. 421-31."},{"key":"key-10.4103\/2229-516X.106347-10","first-page":"956","volume-title":"Hyponatremia and hypernatremia: Disorders of water balance","author":"Agrawal","year":"2008","journal-title":"J Assoc Physicians India"},{"key":"key-10.4103\/2229-516X.106347-11","first-page":"847","volume-title":"Therapeutic potential of vasopressin receptor antagonists","author":"Ali","year":"2007","journal-title":"Drugs"},{"key":"key-10.4103\/2229-516X.106347-12","first-page":"161","volume-title":"Hyponatremia: Diagnosis, complications, and management including V2 receptor antagonists","author":"Elhassan","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key-10.4103\/2229-516X.106347-13","first-page":"1002","volume-title":"Hyponatremia in cirrhosis: Pathogenesis, clinical significance and management","author":"Gines","year":"2008","journal-title":"Hepatology"},{"key":"key-10.4103\/2229-516X.106347-14","unstructured":"Reilly RF, Jackson EK. Regulation of renal function and vascular volume. In: Brunton LL, Chabner BA, Knollman BC, editors. Goodman and Gilman\u2032s the pharmacological basis of therapeutics. 12 th ed. New York: McGraw Hill; 2011. p. 701-19."},{"key":"key-10.4103\/2229-516X.106347-15","first-page":"1624","volume-title":"Non-peptide arginine vasopressin antagonists: The vaptans","author":"Decaux","year":"2008","journal-title":"Lancet"},{"key":"key-10.4103\/2229-516X.106347-16","first-page":"315","volume-title":"Conivaptan: A step forward in the treatment of hyponatremia","author":"Hline","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/2229-516X.106347-17","first-page":"1132","volume-title":"Effects of SR-49059, a V1a vasopressin receptor antagonist, in Raynaud\u2032s phenomenon","author":"Hayoz","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/2229-516X.106347-18","first-page":"104","volume-title":"The effect of relcovaptan (SR 49059), an orally active vasopressin receptor antagonist, on uterine contractions in preterm labour","author":"Steinwall","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"key-10.4103\/2229-516X.106347-19","first-page":"205","volume-title":"The central vasopressinergic system: Examining the opportunities for psychiatric drug development","author":"Ring","year":"2005","journal-title":"Curr Pharm Des"},{"key":"key-10.4103\/2229-516X.106347-20","first-page":"933","volume-title":"Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double -blind multicenter trial","author":"Gerbes","year":"2003","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2229-516X.106347-21","first-page":"1332","volume-title":"Short term clinical effects of tolvaptan, an oral vasopressin antagonist in patients hospitalized for heart failure: The EVEREST clinical status trials","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"key-10.4103\/2229-516X.106347-22","first-page":"1319","volume-title":"Effects of oral Ttolvaptan in patients hospitalized for worsening heart failure.The Everest outcome trial","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"key-10.4103\/2229-516X.106347-23","first-page":"2099","volume-title":"Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-516X.106347-24","first-page":"543","volume-title":"Tolvaptan (Samsca) for hyponatremia: Is it worth its salt?","author":"Reilly","year":"2009","journal-title":"P T"},{"key":"key-10.4103\/2229-516X.106347-25","first-page":"705","volume-title":"SALTWATER Investigators: Oral Tolvaptan is safe and effective in chronic hyponatremia","author":"Berl","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key-10.4103\/2229-516X.106347-26","first-page":"350","volume-title":"Unifying hypothesis of body fluid volume regulation: Implications for cardiac failure and cirrhosis","author":"Schrier","year":"2001","journal-title":"Mt Sinai J Med"},{"key":"key-10.4103\/2229-516X.106347-27","first-page":"447","volume-title":"Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","author":"Zeltser","year":"2007","journal-title":"Am J Nephrol"},{"key":"key-10.4103\/2229-516X.106347-28","first-page":"1149","volume-title":"Tolvaptan and its potential in the treatment of hyponatremia","author":"Dixon","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/2229-516X.106347-29","first-page":"301","volume-title":"Pharmacological profile of YM087, a novel potent vasopressin V1a and V2 receptor antagonist, in vitro and in vivo","author":"Tahara","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/2229-516X.106347-30","first-page":"165","volume-title":"Tolvaptan administration does not affect steady state Amiodarone concentration in patients with cardiac arrhythmias","author":"Shoaf","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"key-10.4103\/2229-516X.106347-31","first-page":"715","volume-title":"Management of hyponatremia: Providing treatment and avoiding harm","author":"Vaidya","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"key-10.4103\/2229-516X.106347-32","first-page":"S1","volume-title":"Hyponatremia treatment guidelines 2007: Expert panel recommendations","author":"Verbalis","year":"2007","journal-title":"Am J Med"},{"key":"key-10.4103\/2229-516X.106347-33","first-page":"980","volume-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"key":"key-10.4103\/2229-516X.106347-34","first-page":"1998","volume-title":"Characterization and prognostic value of persistent hyponatremia in patients with heart failure in the ESCAPE trial","author":"Gheorghiade","year":"2007","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/2229-516X.106347-35","first-page":"680","volume-title":"Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure","author":"Reilly","year":"2010","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2229-516X.106347-36","first-page":"204","volume-title":"Effects of satavaptan, a selective vasopressin V (2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial","author":"Gines","year":"2008","journal-title":"Hepatology"},{"key":"key-10.4103\/2229-516X.106347-37","first-page":"283","volume-title":"Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis","author":"Wong","year":"2010","journal-title":"J Hepatol"}],"container-title":["International Journal of Applied and Basic Medical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:02:40Z","timestamp":1786633360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2229-516X.106347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"alternative-id":["106347"],"URL":"https:\/\/doi.org\/10.4103\/2229-516x.106347","relation":{},"ISSN":["2229-516X"],"issn-type":[{"value":"2229-516X","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}